RXi’s intellectual property estate includes patents and patent applications related to chemistries, sequences, configurations, compounds, delivery technologies, and therapeutic targets. This IP has been developed by RXi as well as in-licensed or acquired from third parties. We believe these patents and patent applications define broad coverage for the development and commercialization of advanced RNAi therapeutics. In particular, they relate to novel and proprietary structural and chemical modification patterns, used to introduce “drug-like” properties to rxRNA® compounds. Fundamental IP related to development of RXi’s rxRNA compounds covers distinct (from conventional siRNAs) structures with duplex length shorter than 15 bases, or longer than 25 bases in the context of advanced and diverse chemical modification patterns.
In 2013, RXi acquired the OPKO RNAi intellectual property estate. The OPKO RNAi estate includes 12 patent families and provides broad patent filings for siRNA compounds which target genes involved in angiogenesis, cancer, immune disorders and inflammatory diseases. Methods for siRNA delivery across the blood-brain and blood-retina barrier are also disclosed for therapeutic and diagnostic use.
RXi also has acquired an exclusive world-wide license to Samcyprone™, a proprietary topical formulation of diphenylcyclopropenone (DPCP). Samcyprone™ is an immunomodulating agent that works by initiating a T-cell response. Our immunomodulator platform patent portfolio provides broad coverage for both compositions and methods of use of Samcyprone™ for the treatment of warts, human papilloma virus (HPV) skin infections, skin cancer (including melanoma) and immunocompromised patients. The FDA has also granted Orphan Drug Designation to RXi for Samcyprone™ for the treatment of Malignant Melanoma Stage IIb to IV. A number of patients with Stage IIb to IV malignant melanoma develop cutaneous metastases.